Audio Coursesby JellypodLesson 04 of 15
Overview
This episode dives into the latest evidence and debates around optimal blood pressure targets after traumatic spinal cord injury. Hosts Jeremy and Hamish discuss guidelines, pathophysiological rationale, and the evolving role of technology and monitoring in ICU and trauma care settings.
Jeremy: Welcome back to TIME, where we slow things down just enough to think clearly about high-stakes acute care. I’m Jeremy
Hamish: And I’m Hamish. Today we’re tackling a question that’s been sitting quietly in trauma ICUs and emergency departments for more than two decades: how hard should we really be pushing blood pressure after acute spinal cord injury?
Jeremy: Specifically, whether the long-standing practice of targeting supranormal MAPs—85 to 90 for days on end—actually improves neurological recovery, or whether it’s one of those things we’ve all inherited without ever truly stress-testing.
Hamish: And for the first time, we finally have randomized trial data to interrogate that question. A 2025 JAMA Network Open study by Sajdeya and colleagues puts some much-needed weight on the scale.
Jeremy: Exhausting, if I’m honest, but worth it. I’ve been buried in trauma data all week, so today’s episode is definitely my happy place! We’re taking on one of critical care’s trickiest challenges: managing blood pressure in acute spinal cord injury. Not glamorous, exactly, but it absolutely matters.
Hamish: It does. It’s frequently controversial, too. For any ICU folks tuning in, you’ll know that mean arterial pressure—MAP—targets in spinal cord injury have become a kind of modern dogma. But… is it justified? That's really what we’re unraveling today.
Jeremy: And we’re going to dig into the rationale, what the best recent study actually tested, and whether those strict MAP goals actually help. Not just from the science, but also the chaos of the trauma bay floor.
Jeremy: The rationale is easy to understand. Secondary spinal cord injury is driven by ischemia, edema, inflammation, and microvascular dysfunction.
Hamish: So the logic followed: if spinal cord blood flow is pressure dependent, then higher systemic pressure should preserve perfusion and limit secondary injury.
Jeremy: That thinking dates back to the 1990s. Vale’s pilot work, small observational cohorts, and later guideline updates in 2013 all converged on the same message—avoid hypotension, and ideally push MAPs higher.
Hamish: But none of that evidence came from randomized trials. It was physiology plus association, layered with expert consensus.
Jeremy: And over time, that consensus hardened into protocol. Seven days. Arterial lines. Vasopressors. ICU admission almost by default.
Hamish: Which brings us to the uncomfortable reality: when practice is built on belief rather than proof, it can persist long after its benefit becomes uncertain.
Jeremy: Let’s ground this in reality. Picture the typical scenario: a middle-aged patient with a high-speed MVC, cervical cord injury, incomplete neurology.
Hamish: They arrive in the ED haemodynamically stable. MAPs are already in the mid-70s. No shock. No hemorrhage.
Jeremy: And yet, within hours, there’s pressure—explicit or implicit—to start vasopressors to “protect the cord,” even though they were never hypotensive to begin with.
Jeremy: That’s the exact population this trial speaks to.
Jeremy: Sajdeya and colleagues conducted a multicentre randomized trial across 13 US Level I trauma centres between 2017 and 2023
Hamish: They enrolled adults with acute traumatic cervical or upper thoracic SCI—C0 to T8—with ASIA grades A to C.
Jeremy: Importantly, they excluded penetrating injuries, lower thoracic injuries, severe TBI, and major comorbidities. This was a deliberately clean SCI cohort
Hamish: Patients were randomized to either an augmented MAP strategy—targeting greater than 85 to 90—or a conventional target of 65 to 70.
Jeremy: Both strategies lasted up to seven days or until ICU discharge.
Hamish: Clinicians weren’t blinded, but six-month neurological assessors were—which matters when your primary outcome is neurological recovery.
Jeremy: The primary outcome was change in ASIA motor and sensory scores at six months.
Hamish: Secondary outcomes included functional independence, mobility, pain, quality of life, and a comprehensive safety profile.
Jeremy: Ninety-two patients were ultimately randomized—fewer than planned, largely due to recruitment challenges and COVID
Hamish: And here’s a key nuance: baseline MAPs in both groups were already reasonable. Hypotension was avoided across the board.
Jeremy: The high-MAP group did achieve higher pressures, but there was overlap. The conventional group often sat in the 70s or low-80s without intervention.
Hamish: Which mirrors modern trauma practice and limits how dramatic the physiological contrast really was.
Jeremy: At six months, there was no statistically or clinically meaningful difference in neurological recovery.
Hamish: Motor scores—upper and lower limbs—were similar. Sensory recovery did not favour aggressive MAPs.
Jeremy: Functional outcomes, mobility, pain, quality of life—again, no signal of benefit.
Hamish: :Mortality was also unchanged.
Jeremy: Let’s pause here, because this is the conceptual hinge of the whole episode
Hamish: Up to this point, everything we’ve talked about could still be framed as a negative trial: no difference, underpowered, maybe inconclusive.
Jeremy: But that framing misses what this study actually tells us. This trial doesn’t test whether blood pressure matters after spinal cord injury. It tests how much it matters once hypotension is already avoided.
Hamish: And that distinction is crucial. In modern trauma care, hypotension is aggressively prevented. Patients arrive earlier, resuscitation is faster, and baseline MAPs are often already acceptable.
Jeremy: So what Sajdeya et al really examined was the incremental value of pushing beyond physiological norms — not rescue from shock, but deliberate hypertension
Hamish: And across neurological recovery, function, and quality of life, that incremental push didn’t move the needle.
Jeremy: Which forces us to ask a harder question: if higher MAPs don’t improve outcomes once a reasonable baseline is achieved, what exactly are we buying with seven days of vasopressors?
Hamish: Especially when we know that spinal cord injury isn’t a single disease. The vascular response, microcirculatory failure, edema, and inflammatory cascades differ wildly between patients.
Jeremy: A uniform MAP target assumes a uniform physiology — and this trial quietly dismantles that assumption.
Hamish: In that sense, this isn’t just a negative trial. It’s a trial that exposes the limits of one-size-fits-all haemodynamic thinking.
Jeremy: Okay, but what about harm? Were there signals that higher MAPs might actually hurt people?
Hamish: Yeah, it’s not all about ‘no benefit’—there’s a safety story too. Pushing MAPs up means more vasopressor use, more risks. In this trial, the higher MAP group actually had more adverse cardiac events—think arrhythmias and ischaemia.
Hamish: Which matches what we see at the bedside sometimes—patients developing complications from aggressive pressor use. I mean, you spend all this time chasing the magic number, and then you maybe tip them into something else.
Jeremy: It’s always a balance, isn’t it? You want to help the cord, but you have to remember the heart, the rest of the patient too.
Jeremy: Now, any time a long-standing practice is challenged, attention naturally turns to limitations
Hamish: And to be fair, this trial has some. The sample size is modest — 92 patients — and recruitment took years.
Jeremy: There was attrition at six months, which is unavoidable in spinal cord injury studies but still matters when neurological outcomes are your endpoint.
Hamish: You could argue that the study was underpowered to detect small differences
Jeremy: But here’s the key point: even if we assume a missed small benefit, we have to ask whether that benefit would justify the observed harms.
Hamish: This wasn’t a trend toward benefit that just failed to reach significance. The outcomes were remarkably flat across domains.
Jeremy: And sensitivity analyses, including imputation for missing data, didn’t change that picture.
Hamish: Another critique is the overlap in achieved MAPs between groups.
Jeremy: But that overlap isn’t a flaw of the trial — it’s a reflection of real-world practice. Modern care already avoids hypotension.
Hamish: If anything, it strengthens external validity. This is exactly how these patients are managed in contemporary EDs and ICUs.
Jeremy: So while the study can’t exclude a very narrow subgroup who might benefit from aggressive augmentation, it strongly argues against routine application
Hamish: And importantly, it shifts the burden of proof. If we’re going to continue aggressive MAP targets, we now need evidence — not tradition — to justify it.
Hamish: Let’s start in the ED, because that’s where these trajectories begin.
Hamish: This trial supports a calm but firm message: early avoidance of hypotension matters, but aggressive vasopressor initiation in a stable SCI patient is not evidence-based.
Jeremy: If a patient arrives with a MAP in the 70s, there is no data here suggesting benefit from pushing them into the high 80s.
Hamish: That matters practically. It means fewer arterial lines, fewer pressors started “just in case,” and less momentum toward automatic ICU escalation.
Jeremy: For intensivists, this trial invites recalibration rather than abandonment of haemodynamic care.
Hamish: It supports stepping away from rigid MAP protocols and toward individualized targets based on overall physiology, comorbidities, and evolving injury patterns.
Jeremy: It also reframes complications we often accept as unavoidable — pneumonia, prolonged ventilation — as potentially iatrogenic.
Hamish: If there’s no neurological upside, those harms deserve much more weight in decision-making.Jeremy:There’s also a systems-level implication here.
Hamish: Aggressive MAP augmentation consumes ICU beds, nursing time, invasive monitoring, and ventilator days.
Jeremy: In resource-constrained trauma systems, that opportunity cost matters — especially when benefit isn’t demonstrated.
Hamish: This trial gives clinicians permission to align care intensity with evidence rather than inertia.
Jeremy: So clinically, the message is not “do less,” but “do what matters.”
Hamish: Avoid hypotension early. Stabilize aggressively when needed. But don’t confuse escalation with excellence.
Jeremy: And recognize that spinal cord injury care is likely moving toward perfusion-guided and patient-specific strategies — not universal MAP thresholds.
Jeremy: When practices persist for decades, they often stop feeling like decisions and start feeling like facts. Blood pressure augmentation after acute spinal cord injury is a perfect example of that.
Hamish: For years, targeting MAPs of 85 to 90 has been treated as a marker of high-quality care—something you do because not doing it feels unsafe. But what this trial forces us to confront is that plausibility is not the same as proof.
Jeremy: Sajdeya and colleagues didn’t show that blood pressure doesn’t matter. They showed something more precise—and more uncomfortable: that once hypotension is avoided, pushing pressure beyond normal physiology does not translate into better neurological recovery.
Hamish: And critically, it’s not a neutral intervention. Aggressive MAP augmentation isn’t just a number on a monitor—it’s arterial lines, vasopressors, fluids, ventilators, ICU days, and complications that patients actually experience.
Jeremy: The implication here isn’t that we should be passive. It’s that we should be deliberate. This study supports a model of care that prioritises early stabilisation, meticulous avoidance of hypotension, and thoughtful escalation rather than automatic hypertension
Hamish: It also highlights a broader pattern we see repeatedly in critical care: system-wide practices built on observational data often look convincing until they’re tested properly. When they are, the benefits tend to be smaller—and the harms more visible—than we expected.
Jeremy: For emergency clinicians, the message is reassuring. You don’t need to chase supranormal pressures in a haemodynamically stable SCI patient to be delivering evidence-based care.
Hamish: And for intensivists, it opens the door to recalibration—less protocol-driven hypertension, more individualised physiology, and greater attention to downstream harm.
Jeremy: Where the field likely moves next isn’t toward another fixed MAP target, but toward better markers of spinal cord perfusion and injury-specific haemodynamics.
Hamish: Until then, this trial gives us permission—backed by randomized data—to step away from reflexive blood pressure augmentation and refocus on what actually improves outcomes.
Jeremy: Avoid hypotension. Respect physiology. And be honest about the difference between what makes sense and what truly helps.
Jeremy: If you value deep, evidence-based discussion like this, you’ll find it across TIME.
Hamish: And if you’re preparing for Australian critical care exams, check out Clintix Pro—an AI-powered study companion built for emergency, ICU, and anaesthetic trainees.
Jeremy: High-yield content. Structured reasoning. Less wasted time.
Hamish: We’ll also be sharing details soon about our next CME event. Keep an eye on clintix.com.
Jeremy: Thanks for listening to TIME. Until next time.
